Lin, J., Lu, Y., Zhang, H., Chen, P., Wang, D., Chen, Y. (2026). Tofacitinib for immune-related adverse events ≥ grade 3 induced by immune checkpoint inhibitors: A single-arm, open-label, two-stage study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.19_suppl.81